The Open cancer immunology journal最新文献_第2页

Editorial - Brain Tumor Immunotherapy 社论-脑肿瘤免疫治疗

The Open cancer immunology journal Pub Date : 2010-12-31 DOI: 10.2174/1876401001003010022

T. Lichtor

引用次数: 0

Immunotherapy targeted at brain cancer stem cells 针对脑癌干细胞的免疫疗法

The Open cancer immunology journal Pub Date : 2010-12-31 DOI: 10.2174/1876401001003010048

M. Toda

引用次数: 0

Receptor-Independent Metabolic Effects of Thiazolidinediones in Astrocytes 噻唑烷二酮在星形胶质细胞中不依赖受体的代谢作用

The Open cancer immunology journal Pub Date : 2010-12-31 DOI: 10.2174/1876401001003010036

C. Akar, S. Kalinin, V. Gavrilyuk, A. Spagnolo, G. Weinberg, D. Feinstein

{"title":"Receptor-Independent Metabolic Effects of Thiazolidinediones in Astrocytes","authors":"C. Akar, S. Kalinin, V. Gavrilyuk, A. Spagnolo, G. Weinberg, D. Feinstein","doi":"10.2174/1876401001003010036","DOIUrl":"https://doi.org/10.2174/1876401001003010036","url":null,"abstract":"Thiazodinedione (TZD) agonists of the peroxisome proliferator activated receptor gamma (PPAR￻ ) exert meta- bolic effects in glial cells. In primary astrocytes, TZDs are cytoprotective and have anti-inflammatory actions; in contrast, in glioma cells TZDs are cytotoxic. Although PPAR￻ is considered their primary target, TZDs including pioglitazone and troglitazone also bind to a mitochondrial protein MitoNEET; whether their metabolic effects are mediated by activation of PPAR￻ or MitoNEET are not known. We generated PPAR￻ null astrocytes by crossing a PPAR￻ floxxed mouse with a transgenic line expressing CRE recombinase under control of the GFAP promoter. PPAR￻ deficient astrocytes showed reduced lactate production under basal conditions and in response to pioglitazone; however at later times similar levels of lactate were produced. In the presence of troglitazone lactate production was similar in PPAR￻ null cells as wildtype as- trocytes. In astrocytes in which MitoNEET expression was reduced using siRNA, basal lactate production was lower than control cells, however the cells increased lactate production in response to TZDs. When MitoNEET was decreased in the PPAR￻ null astrocytes, responses to TZDs were reduced compared to non-infected cells. These results indicate that meta- bolic effects of TZDs are not exclusively mediated via PPAR￻ , but involve binding to MitoNEET. Real time PCR revealed significantly greater MitoNEET mRNA in glioma cells than astrocytes. Differences in MitoNEET expression or activity could therefore contribute to differential effects of TZDs on astrocyte versus glioma cells.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"3 1","pages":"36-40"},"PeriodicalIF":0.0,"publicationDate":"2010-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68135741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Recurrences of Superficial Bladder Carcinoma are Associated with a Raise of CD8highCD57+ and CD8low T Lymphocytes in Peripheral Blood 浅表性膀胱癌复发与外周血CD8highCD57+和CD8low T淋巴细胞升高有关

The Open cancer immunology journal Pub Date : 2010-11-11 DOI: 10.2174/1876401001003010008

J. Jacobs, D. Characiejus, Vita Paukonien, Feliksas Jankeviius, R. V. Moorselaar, M. Mauricas, W. Otter

{"title":"Recurrences of Superficial Bladder Carcinoma are Associated with a Raise of CD8highCD57+ and CD8low T Lymphocytes in Peripheral Blood","authors":"J. Jacobs, D. Characiejus, Vita Paukonien, Feliksas Jankeviius, R. V. Moorselaar, M. Mauricas, W. Otter","doi":"10.2174/1876401001003010008","DOIUrl":"https://doi.org/10.2174/1876401001003010008","url":null,"abstract":"Immunotherapy with BCG is effective in patients with recurrent superficial bladder carcinoma. This therapy involves Interleukin-2 (IL-2), but little is known about the immunological parameters involved in superficial bladder car- cinoma. We have monitored immunological parameters in twenty patients with superficial bladder carcinoma treated with transurethral resection (TUR) followed by IL-2 instillation. Cell numbers of peripheral blood leukocyte subpopulations were counted before surgery and during follow-up after surgery. During follow-up, we compared the cell counts in pa- tients with and without a recurrent tumour. We used the values of healthy matched controls as a reference. Recurrent dis- ease in patients corresponded with a significant increase in CD8 + lymphocytes, and especially the CD8 high CD57 + and CD8 low subpopulations. The phenotype of these T lymphocytes belongs to cells with an immunosuppressive function. We hypothesize that these peripheral immune suppressive cells facilitate tumour recurrences or that tumour recurrences cause an increase in peripheral immune suppressive lymphocytes.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"3 1","pages":"8-14"},"PeriodicalIF":0.0,"publicationDate":"2010-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68134327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Improvement of Anti-Tumor DNA Vaccination by Co-Immunization at a Distant Site with a Plasmid Encoding the Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus 用编码新城疫病毒血凝素-神经氨酸酶蛋白的质粒远距离联合免疫改进抗肿瘤DNA疫苗接种

The Open cancer immunology journal Pub Date : 2010-11-11 DOI: 10.2174/1876401001003010015

Jing Ni, V. Schirrmacher, P. Fournier

{"title":"Improvement of Anti-Tumor DNA Vaccination by Co-Immunization at a Distant Site with a Plasmid Encoding the Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus","authors":"Jing Ni, V. Schirrmacher, P. Fournier","doi":"10.2174/1876401001003010015","DOIUrl":"https://doi.org/10.2174/1876401001003010015","url":null,"abstract":"DNA vaccine encoding tumor associated antigens (TAAs) is an attractive strategy for tumor vaccine develop- ment. But its efficacy to induce efficient anti-tumor immunity needs to be improved. In this study, we combined immuni- zation with such a plasmid at the ear pinna site (i.e.) with co-immunization with another plasmid (pHN) encoding the He- maglutinin-Neuraminidase (HN) protein of the NDV virus at a subcutaneous site. We first tested a prophylactic immuni- zation protocol followed by subcutaneous challenge with the ESb-lacZ lymphoma expressing the ￻ -galactosidase protein as a surrogate tumor antigen. While i.e. vaccination with the placZ plasmid reduced tumor growth, the additional s.c. im- munization with the pHN plasmid further improved this effect. We next tested a therapeutic tumor model based on the mammary carcinoma DA3-hEpCAM expressing the human EpCAM molecule. Efficient reduction of tumor growth was achieved by immunization of tumor-bearing mice with DNA plasmids encoding the human EpCAM gene only when it was combined with s.c. application of the pHN plasmid. A significantly better cross-protection against a second challenge with the parental DA3 tumor cells was only observed when mice were initially co-immunized with both plasmids. These results demonstrate that co-immunization of a plasmid encoding the HN protein of NDV and a DNA vaccine en- coding a tumor antigen significantly reduced tumor growth in mouse tumor models employing both prophylactic and therapeutic vaccination strategies. These observations point towards the HN protein of NDV as a powerful molecular ad- juvant for DNA vaccines.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"3 1","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2010-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68134348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Vitro Activation of Cytotoxic T Lymphocytes By Muc1 Pulsed Dendritic Cells~!2009-03-16~!2009-09-12~!2010-01-02~! Muc1脉冲树突状细胞体外活化细胞毒性T淋巴细胞的研究

The Open cancer immunology journal Pub Date : 2010-01-04 DOI: 10.2174/1876401000902010031

F. Kryukov, D. Ocadlikova, L. Kovarova, I. Burešová, E. Matějková, R. Hájek, J. Michálek

引用次数: 0

HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy. HLA II类抗原在前列腺癌细胞中的呈递:前列腺肿瘤免疫治疗的新途径。

The Open cancer immunology journal Pub Date : 2010-01-01 DOI: 10.2174/1876401001003010001

Bently Patrick Doonan, Azizul Haque

{"title":"HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.","authors":"Bently Patrick Doonan, Azizul Haque","doi":"10.2174/1876401001003010001","DOIUrl":"https://doi.org/10.2174/1876401001003010001","url":null,"abstract":"<p><p>Prostate cancer is a deadly disease that is in drastic need of new treatment strategies for late stage and metastatic prostate cancer. Immunotherapy has emerged as a viable option to fill this void. Clinical trials have been conducted that induce tumor clearance through cytotoxic T lymphocyte (CTL) activation, these studies have had mixed outcomes with the overlying problem being the lack of a complete immune response with sustained killing and the formation of tumor specific memory cells. To overcome this, we have outlined the need for activating the HLA class II pathway in inducing a sustained CD8+ T cell response and the development of effective memory. We have also discussed the ability of prostate cancer cells to express stable HLA class II molecules that can be manipulated for tumor antigen (Ag) processing and presentation. This review also sets to outline new directions that exist for the use of class II-restricted Ags/peptides in devising cancer vaccines as well as combined chemoimmunotherapy. A better understanding of these concepts will improve future cancer vaccine studies and further the field of cancer immunobiology.</p>","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"3 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807132/pdf/nihms434202.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40270405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Ear Pinna : a privileged DNA electroporation site for inducing strong Th1 immune responses 耳廓:一个特殊的DNA电穿孔部位，可诱导强烈的Th1免疫反应

The Open cancer immunology journal Pub Date : 2009-12-02 DOI: 10.2174/1876401000902010018

Jing Ni, B. Nolte, G. Vandermeulen, V. Préat, D. Scherman, V. Schirrmacher, P. Fournier

{"title":"Ear Pinna : a privileged DNA electroporation site for inducing strong Th1 immune responses","authors":"Jing Ni, B. Nolte, G. Vandermeulen, V. Préat, D. Scherman, V. Schirrmacher, P. Fournier","doi":"10.2174/1876401000902010018","DOIUrl":"https://doi.org/10.2174/1876401000902010018","url":null,"abstract":"DNA vaccination appears a very attractive approach for inducing immune responses towards the encoded anti- gen, but studies in large animals and in humans revealed weaknesses of such responses. In this study, we evaluated a new approach based on a new device combining DNA vaccination with electroporation (EP) at the ear pinna site. Under opti- mal EP conditions, the expression of the DNA encoded antigen and the induced immune responses were considerably in- creased. Very interestingly, DNA vaccination using EP at the ear pinna induced much stronger cellular immune responses than at the flank skin although antigen expression was similar at both sites. As compared to vaccination at the ear pinna without EP, IFN-￻ but not IL-4 production by splenocytes from immunized mice was significantly enhanced. In contrast, IL-4 but not IFN-￻ production was increased by EP at the flank skin. The vaccination site of the ear pinna combined with EP route even provided therapeutic effects in a mouse tumor model. In conclusion, this study highlights the ear pinna as a privileged site for the induction of strong Th1 polarized cellular im- munity against a defined antigen when combining DNA vaccination with EP.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"4 1","pages":"18-30"},"PeriodicalIF":0.0,"publicationDate":"2009-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68134276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Hydroxyl Radical Damaged Thymidine-5'-Monophophate Presents Unique Epitopes for Cancer Antibodies 羟基自由基损伤胸苷- 5'-单磷酸腺苷为癌症抗体提供独特的表位

The Open cancer immunology journal Pub Date : 2009-11-10 DOI: 10.2174/1876401000902010010

R. Ahmad, Z. Rasheed, R. Ali

{"title":"Hydroxyl Radical Damaged Thymidine-5'-Monophophate Presents Unique Epitopes for Cancer Antibodies","authors":"R. Ahmad, Z. Rasheed, R. Ali","doi":"10.2174/1876401000902010010","DOIUrl":"https://doi.org/10.2174/1876401000902010010","url":null,"abstract":"Reactive oxygen species (ROS) plays an important role in carcinogenesis and hydroxyl radical ( . OH) contrib- utes to the structural changes in DNA that characterize the cancer like phenotype. The role of hydroxyl radical ( . OH) dam- aged thymidine 5'-monophosphate (TMP) in cancer patients has been investigated in the present study. TMP was conju- gated to bovine serum albumin (BSA), and then TMP-BSA conjugate was modified by hydroxyl radicals. Cancer patients (n = 99) were screened by direct binding ELISA for the detection of antibodies against native and ROS-modified conju- gates and the results were compared with healthy age-matched controls (n = 29). High degree of specific binding by can- cer serum antibodies towards ROS modified TMP-BSA conjugate, in comparison to unmodified conjugate (p<0.05) was observed. Healthy individuals showed negligible binding with either antigen. Competitive inhibition ELISA reiterates the direct binding results. Protein-A affinity purified IgG from cancer patients further substantiated the enhanced recognition towards modified conjugate as compared to unmodified conjugate. The present study clearly shows the perturbation in TMP-BSA conjugate by hydroxyl radical presenting unique neo-epitopes on TMP that might from one of the factors in antigen driven induction of antibodies in cancer patients.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"6 1","pages":"10-17"},"PeriodicalIF":0.0,"publicationDate":"2009-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68134267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A Systematic Review of Economic Analyses Studying Rituximab in R-CHOP Therapy in Patients with Non-Hodgkin Lymphoma 非霍奇金淋巴瘤患者R-CHOP治疗中利妥昔单抗经济分析的系统综述

The Open cancer immunology journal Pub Date : 2009-09-18 DOI: 10.2174/1876401000902010001

J. Yoder, K. Kamal

{"title":"A Systematic Review of Economic Analyses Studying Rituximab in R-CHOP Therapy in Patients with Non-Hodgkin Lymphoma","authors":"J. Yoder, K. Kamal","doi":"10.2174/1876401000902010001","DOIUrl":"https://doi.org/10.2174/1876401000902010001","url":null,"abstract":"Objectives: To explore the use of pharmacoeconomic principles through examination of economic evaluations pertaining to the combination of the monoclonal antibody rituximab with conventional CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone) or CHOP-like chemotherapy regimens in patients with non-Hodgkin lymphoma. Methods: A literature search was conducted using Evidence-Based Medical Reviews (EBMR), International Pharmaceutical Abstracts (IPA), and Medline databases to identify all economic studies relating to rituximab in combination with CHOP or CHOP-like regimens. The systematic evaluation also utilized the Quality of Health Economic Studies instrument to assess the quality of each study that was included in the final review. Results: Initially, eight studies were retrieved which included the use of rituximab in non-Hodgkin lymphoma treatment. Of these, four studies were excluded as rituximab was used as a stand-alone treatment option. The remaining four studies involved conventional CHOP therapy versus the combination with rituximab (R-CHOP) in patients with non-Hodgkin lymphoma. One study employed a cost-effectiveness analysis while the remaining three studies used a cost-utility analysis and reported the outcomes in terms of quality-adjusted life years (QALYs). Conclusions: The cost-effectiveness evaluation illustrated the dominance of R-CHOP over CHOP-alone in terms of both lower costs and increased life years gained. The cost-utility of R-CHOP in terms of costs/QALYs were below the accepted threshold of 50,000 in international monetary units. Through examination of evaluation principles employed, it is found that valid results are highly dependent on the input data, assumptions, and sensitivity analyses. Clinical decisionmakers must take into account specific inclusions of costs relevant to their own practice setting.","PeriodicalId":93682,"journal":{"name":"The Open cancer immunology journal","volume":"2 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2009-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68134211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4